Anti-NaPi2b Antibody CDR Engineering for Targeted ADC Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing NaPi2b-targeted antibody-drug conjugates have shown mixed results in clinical trials for treating cancers like ovarian and lung cancer, with some trials being discontinued due to lack of efficacy or toxicity issues, highlighting the need for improved antibodies with enhanced specificity and efficacy.
Innovation Solution
Development of anti-NaPi2b antibodies with specific antigen-binding domains, including defined CDR sequences, and their conjugation with drug moieties to form antibody-drug conjugates (ADCs) for targeted cancer therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing NaPi2b-targeted antibody-drug conjugates are used in clinical trials, then cancer treatment is attempted, but mixed results are obtained with some trials discontinued due to lack of efficacy or toxicity issues
Solution Approach 1:
The patent applies local quality by engineering specific CDR sequences (HCDR1: SEQ ID NO: 7, HCDR2: SEQ ID NO: 8, HCDR3: SEQ ID NO: 9, LCDR1: SEQ ID NO: 19, LCDR2: SEQ ID NO: 20, LCDR3: SEQ ID NO: 18) to optimize binding to specific epitopes on NaPi2b in cancer cells. This localized optimization of antibody structure at the antigen-binding site enhances specificity for tumor cells while reducing off-target toxicity, directly addressing the contradiction between efficacy and safety
Solution Approach 2:
The patent employs parameter changes by modifying key structural parameters of the antibody including the amino acid sequences of all six CDR regions and the framework regions. These parameter optimizations result in improved binding affinity (lower KD values) and enhanced internalization efficiency, thereby improving therapeutic efficacy while maintaining safety profile
2Reliability
If antibody constructs with optimized CDR sequences are developed, then binding affinity and internalization are improved, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into distinct functional modules with specifically optimized CDR sequences (HCDR1-3 and LCDR1-3) and framework regions. Each CDR is independently designed and optimized for its specific role in antigen recognition and binding, allowing systematic optimization of binding affinity without requiring complete redesign of the entire antibody structure
Solution Approach 2:
The patent employs universality by designing an antibody construct where the optimized CDR sequences can bind to conserved epitopes on NaPi2b across different cancer types (ovarian, lung, endometrial cancer). This multi-functional design allows a single antibody construct to achieve high binding affinity across multiple cancer indications, reducing development complexity compared to creating separate antibodies for each cancer type
Data Source
AI summary
Described herein are antibody constructs that bind human NaPi2b (or SLC34A2) and antibody-drug conjugates (ADCs) comprising an anti-NaPi2b antibody construct conjugated to a drug, such as a cytotoxin or an immune modulator, and their use as therapeutics or diagnostics, for example, in the treatment or diagnosis of cancer.